EcoDrugPlus

Ttk Protein Kinase

Ensembl ID : ENSCSEG00000009378
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSCSEG00000020477
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSCSEG00000001192
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSCSEG00000000393
Gene Symbol: YES1
4 Cross references
197 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSCSEG00000014888
Gene Symbol: ACHE
1 Cross references
232 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSCSEG00000016626
Gene Symbol: ACVR2B
3 Cross references
196 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSCSEG00000018448
Gene Symbol: ACVR2BA
1 Cross references
194 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSCSEG00000005023
Gene Symbol: ADORA1
3 Cross references
208 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSCSEG00000003550
Gene Symbol: ADORA2A
3 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSCSEG00000009764
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSCSEG00000001717
Gene Symbol: LOC103384601
3 Cross references
201 Possible Orthologues:

Adenosine Receptor A2a

Ensembl ID : ENSCSEG00000010259
Gene Symbol: LOC103397442
3 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).